Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy

Radiology

Volumn 234, Issue 3, 2005, Pages 804-814

  Zakian, Kristen L ^a   Sircar, Kanishka ^a   Hricak, Hedvig ^a   Chen, Hui Ni ^a   Shukla Dave, Amita ^a   Eberhardt, Steven ^a   Muruganandham, Manickam ^a   Ebora, Lanie ^a   Kattan, Michael W ^a   Reuter, Victor E ^a   Scardino, Peter T ^a   Koutcher, Jason A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

ADULT; AGED; BIOPSY; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTONS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SIGNAL PROCESSING, COMPUTER-ASSISTED;

EID: 13844296966     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2343040363     Document Type: Article

References (44)

1. Kattan MW, Eastham JA, Stapleton AMF, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90:766-771.
2. Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000; 18:3352-3359.
3. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274:626-631.
4. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsn PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169:517-523.
5. Partin AW, Piantadosi S, Sanda MG, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995; 45:831-838.
6. Bauer JJ, Connelly RR, Seterhenn IA, et al. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol 1998; 159:929-933.
7. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17:1499-1507.
8. Cookson MS, Fleshner NE, Soloway SM, Fair WR. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol 1997; 157:559-562.
9. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology 1999; 213:473-480.
10. 3) spatial resolution. Radiology 1996; 198:795-805.
11. Star-Lack J, Nelson SJ, Kurhanewicz J, Huang LR, Vigneron DB. Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn Reson Med 1997; 38:311-321.
12. Moyher SE, Vigneron DB, Nelson SJ. Surface coil MR imaging of the human brain with an analytic reception profile correction. J Magn Reson Imaging 1995; 5:139-144.
13. Vigneron DB, Nelson SJ, Moyher S, Kelley D, Kurhanewicz J, Hricak H. An analytical correction of MR images obtained with endorectal or surface coils. J Magn Reson Imaging 1993; 3:142-145.
14. 1H MRS data for the assessment of response to therapy in patients with brain tumors (abstr). In: Proceedings of the Society of Magnetic Resonance in Medicine and the European Society of Magnetic Resonance in Medicine and Biology. Berkeley, Calif: Society of Magnetic Resonance in Medicine, 1995; 1960.
15. Bottomley P. Selective volume method for performing localized NMR spectroscopy. USA patent 4, 1984; 480:228.
16. Brown TR, Kincaid BM, Ugurbil K. NMR chemical shift imaging in three dimensions. Proc Natl Acad Sci U S A 1982; 79:3523-3526.
17. Males R, Vigneron D, Star-Lack J, et al. Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn Reson Med 2000; 43:17-22.
18. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrics 1986; 73:13-22.
19. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000; 164:400-404.
20. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997; 21:566-576.
21. Males R, Vigneron D, Nelson S, et al. Addition of MR spectroscopic imaging to MRI significantly improves detection and localization of prostate cancer (abstr). In: Proceedings of the Sixth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 1998; 487.
22. Vigneron DB, Males R, Noworolski S, et al. 3D MRSI of prostate cancer: correlation with histologic grade (abstr). In: Proceedings of the Sixth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 1998; 488.
23. Zakian KL, Sircar K, Kleinman S, Shukla-Dave A, Kattan MW, Hricak H. Correlation of proton MR spectroscopic imaging with Gleason score based on step section radical prostatectomy (abstr). Radiology 2002; 225(P):1525.
24. Gleason DF, Group VACU. Histologic grading and clinical staging of prostatic carcinoma. In: Tannebaum M, ed. Urologic pathology: the prostate. Philadelphia, Pa: Lea & Febiger, 1977; 171-197.
25. Swanson MG, Vigneron DB, Tabatabai ZL, et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MR imaging and 3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med 2003; 50:944-954.
26. Fulham MJ, Bizzi A, Dietz MJ, et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 1992; 185:675-686.
27. 1H magnetic resonance spectroscopy. Surg Neurol 1995; 44:137-144.
28. Heesters MA, Kamman RL, Mooyaart EL, Go KG. Localized proton spectroscopy of inoperable brain gliomas: response to radiation therapy. J Neurooncol 1993; 17:27-35.
29. 1H MR spectroscopy in patients with metastatic brain tumors: a multicenter study. Magn Reson Med 1995; 33:818-826.
30. Rutter A, Hugenholtz H, Saunders JK, Smith ICP. One-dimensional phosphorus-31 chemical shift imaging of human brain tumors. Invest Radiol 1995; 30:359-366.
31. Koutcher JA, Ballon D, Graham M, et al. P-31 NMR spectra of extremity sarcoma: diversity of metabolic profiles and changes in response to chemotherapy. Magn Reson Med 1990; 16:19-34.
32. Dewhirst MW, Sostman HD, Leopold KA, et al. Soft-tissue sarcomas: MR imaging and MR spectroscopy for prognosis and therapy monitoring: work in progress. Radiology 1990; 174:847-853.
33. Smith TA, Eccles S, Ormerod MG, Tombs AJ, Titley JC, Leach MO. The phosphocholine and glycerophosphocholine content of an oestrogen-sensitive rat mammary tumour correlates strongly with growth rate. Br J Cancer 1991; 64:821-826.
34. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999; 59:80-84.
35. Sakr WA, Tefilli MV, Grignon DJ, et al. Gleason score 7 prostate cancer: a heterogeneous entity? correlation with pathologic parameters and disease-free survival. Urology 2000; 56:730-734.
36. Han M, Snow PB, Epstein JI, et al. A neural network predicts progression for men with Gleason score 3 + 4 versus 4 + 3 tumors after radical prostatectomy. Urology 2000; 56:994-999.
37. Herman CM, Kattan MW, Ohori M, Scardino PT, Wheeler TM. Primary Gleason pattern as a predictor of disease progression in Gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol 2001; 25:657-660.
38. Eichelberger LE, Koch MO, Daggy JK, Ulbright TM, Eble JN, Cheng L. Predicting tumor volume in radical prostatectomy specimens from patients with prostate cancer. Am J Clin Pathol 2003; 120:386-391.
39. Augustin H, Hammerer PG, Graefen M, et al. Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy. J Cancer Res Clin Oncol 2003; 129:662-668.
40. Zakian KL, Eberhardt S, Hricak H, et al. Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging-initial results. Radiology 2003; 229:241-247.
41. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988; 12:897-906.
42. Shukla-Dave A, Koutcher JA, Eberhardt S, et al. 1H MRSI findings in prostatitis (abstr). In: Proceedings of the Eleventh Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2003; 1291.
43. Murphy-Boesch J, Jiang H, Stoyanova R, Brown TR. Quantification of phosphorus metabolites from chemical shift imaging spectra with corrections for point spread effects and B1 inhomogeneity. Magn Reson Med 1998; 39:429-438.
44. Hugg JW, Maudsley AA, Weiner MW, Matson GB. Comparison of k-space sampling schemes for multidimensional MR spectroscopic imaging. Magn Reson Med 1996; 36:469-473.